Epilepsy affects approximately 50 million people worldwide [1]. Despite many years of research and a large number of antiseizure medication that inhibit neurotransmission and excessive stimulation of neurones, approximately 30% of patients fail to achieve seizure freedom [2]. Regardless of the aetiology of epilepsy, additional processes such as inflammation and related damage to the blood-brain barrier (BBB) integrity may affect the course of the disease and the response to treatment [3]. Clinical observations have demonstrated that adrenocortical hormones (ACTH) and steroids have antiseizure properties in certain childhood epilepsies [4].
19
FEB
FEB
0